ClinicalTrials.gov
public full text
Public Domain
Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
Study CV-0002 is the first clinical trial administering CV-MG01 in humans. This clinical trial is a safety and proof-of-concept study (proof of mechanism of action) intended to assess the safety, tolerability and immunogenic response following 3 subcutaneous injections of CV-MG01 as a potential therapeutic vaccine / active immunotherapy in myasthenia gravis (MG) patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients#872770
- Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360#860433
- Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)#802702
- Vitaccess Real MG Registry#854910
- A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults#417598
Record · ID 846146
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive